Introduction {#Sec1}
============

The rough endoplasmic reticulum (rER) has stringent quality control mechanisms to ensure that only properly folded proteins are allowed to leave the rER, thus mediating the secretion of high-quality functional proteins (Kaufman [@CR14], [@CR15]; Rutkowski and Kaufman [@CR26]). Correctly folded proteins are translocated to the Golgi apparatus where they undergo additional processing before trafficking to their intended destinations, either secretion into the extracellular matrix (ECM) or embedding in the plasma membrane or to the lysosome.

A number of protein folding disorders result from the accumulation of unfolded or misfolded proteins within the rER, causing ER stress (Kaufman [@CR15]). This ER stress can lead to an upregulation of many rER resident proteins involved in protein folding to protect the cells from the ER stress and is known as an unfolded protein response (UPR).

The chondrodysplasias are a clinically and genetically heterogeneous group of over 200 unique phenotypes that effect the development of the osseous skeleton (Hall [@CR10]). Numerous chondrodysplasias can result from mutations in the genes encoding cartilage extracellular matrix proteins (Superti-Furga et al. [@CR30]) that can sometimes lead to misfolding and an accumulation of mutant protein within the rER (Bateman et al. [@CR2]; Boot-Handford and Briggs [@CR3]). Mutant protein accumulation in the rER is a key pathological feature in a range of different mouse models of chondrodysplasias, primary amongst which are models of pseudoachondroplasia, multiple epiphyseal dysplasia (Leighton et al. [@CR17]; Schmitz et al. [@CR28]) and metaphyseal chondrodysplasia type Schmid (MCDS; Ho et al. [@CR12]; Rajpar et al. [@CR24]; Tsang et al. [@CR32]).

Multiple epiphyseal dysplasia (MED) is a clinically variable and genetically heterogeneous chondrodysplasia that is characterised by mild short stature, joint pain and stiffness and early onset osteoarthritis. Autosomal-dominant forms of MED can result from mutations in the genes encoding three cartilage structural proteins, cartilage oligomeric matrix protein, type IX collagen and matrilin-3 (Briggs and Chapman [@CR4]). Matrilin-3 is the third member of a family of four ECM proteins; matrilin-1 and matrilin-3 are primarily expressed in cartilage, whilst matrilin-2 and matrilin-4 have a wider pattern of expression in a variety of ECM including non-skeletal tissues (Wagener et al. [@CR34]).

Matrilin-3 consists of a single von Willebrand factor A-like domain (A-domain), four epidermal growth factor (EGF)-like motifs and a coiled-coil oligomerization domain (Wagener et al. [@CR33]). All of the MED-causing mutations in *MATN3* are found in the single A-domain of matrilin-3 in either the β-strand or α-helix regions (Fresquet et al. [@CR9]; Jackson et al. [@CR13]). The majority of these mutations have been shown to result in the retention of mutant protein in vitro, whereas a smaller proportion of mutations appear to allow the secretion of mutant protein (Cotterill et al. [@CR7]; Fresquet et al. [@CR9]).

In order to determine the precise disease mechanisms that underpin the pathophysiology of MED in vivo, we generated a murine model by introducing a disease-causing *Matn3* mutation (p.V194D). This mouse model exhibited significant short-limb dwarfism with a marked reduction in chondrocyte proliferation and dysregulated apoptosis within the cartilage growth plates of the developing limbs. Mutant matrilin-3 was retained within the rER of chondrocytes, and preliminary experiments demonstrated the upregulation of BiP and Grp94 in chondrocytes from 4-day-old mice (Leighton et al. [@CR17]).

The aim of this current study was to use microarray, quantitative real-time reverse-transcriptase polymerase chain reaction (qRT-PCR) and Western blotting to comprehensively characterise the initial cellular response in the post-natal stage of the disease.

Materials and methods {#Sec2}
=====================

Real-time PCR and Western blot analysis {#Sec3}
---------------------------------------

For qRT-PCR, the rib cages from 5-day-old mice (wild type (wt) and mutant (m/m)) were dissected and treated with collagenase (type 1A, 2 mg/ml) for 1 h at 37°C in Dulbecco's modified Eagle's medium (DMEM). The costal cartilage was dissected from individual ribs, and the perichondrium layer was removed. The cartilage was digested a second time with collagenase for 3 h to remove the collagen matrix and release the chondrocytes. The chondrocytes were passed through a cell strainer (70 μm) and washed with DMEM containing 10% FBS and following centrifugation washed again with PBS. The cell pellet was resuspended in 500 μl TriZol (Invitrogen), and total RNA was isolated according to the manufacturer's instructions. First-strand cDNA was synthesised using random hexamer primers (Superscript III, Invitrogen), and qPCR was performed using the SYBR® green PCR protocol. Primer sequences were: BiP: 5′-ggcaccttcgatgtgtctcttc-3′ and rev: 5′-tccatgacccgctgatcaa-3′; Grp94: 5′-taagctgtatgtacgccgcgt-3′ and rev: 5′-ggagatcatcggaatccacaac-3′; Calnexin: 5′-tga ttt cct ctc cct ccc ctt-3′ and rev: 5′-cac tgg aac ctg ttg atg gtg a-3′; Calreticulin: 5′-gct acg tga agc tgt ttc cga-3′ and rev: 5′-aca tga acc ttc ttg gtg cca g-3'; Erp72: 5′-agt atg agc cca ggt tcc acg t-3′ and rev: 5′-aga agt ctt acg atg gcc cac c-3′. Each experiment included 'no template' controls, was run in duplicate and had an 18S RNA control. Each independent experiment was repeated three times, and the results were analysed by independent-samples *t* test.

For Western blot analysis, chondrocytes were isolated as above, but aliquots of 2 × 10^5^ chondrocytes were prepared and resuspended in 5× sodium dodecyl sulphate (SDS) loading buffer containing DTT. These protein aliquots were separated by 4--12% SDS-polyacrylamide gel electrophoresis (PAGE; Invitrogen) then transferred to nitrocellulose membranes for Western blot analysis. Ponceau staining was used to confirm equal loading of total protein isolates.

Antibodies to key chaperones associated with the unfolded protein response were used at a dilution of either 1:500 (BiP, Grp94, Erp72 and PDI; all from Santa Cruz) or 1:100 (ATF-6 from Imgenex and Bcl-2 from Abcam).

Histology and immunohistochemistry {#Sec4}
----------------------------------

Tissue samples were fixed overnight in ice-cold 10% formalin (haematoxylin and eosin (H&E) staining and Terminal deoxynucleotidyl transferase dUTP nick-end labelling (TUNEL)) or 95% ethanol and 5% acetic acid (immunohistochemistry (IHC) and bromodeoxyuridine (BrdU)). Samples were then decalcified in 20% EDTA and embedded in paraffin wax as described previously (Leighton et al. [@CR17]). Antibodies used were rabbit anti-matrilin-3 (R&D), rat anti-BrdU (Abcam) and goat anti-Grp94 (Santa Cruz). Briefly, endogenous peroxidase activity was quenched by a H~2~O~2~/methanol wash, followed by hyaluronidase treatment. Samples were blocked with goat serum (for anti-matrilin-3 and anti-BrdU) or rabbit serum (for anti-Grp94) and bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 1 h and incubated for 1 h with the primary antibody (in PBS/BSA). They were then incubated for 1 h with the relevant secondary antibodies such as biotinylated goat anti-rabbit IgG (Dako Cytomation), biotinylated goat anti-rat (Abcam) or rabbit anti-goat (Santa Cruz) in PBS/BSA with goat/rabbit serum. Slides were then incubated with the ABC complex/HRP reagent for 30 min and developed using DAB. Samples were counterstained with methyl green and mounted with VectaMount. BrdU IHC was performed as above, except the hyaluronidase step was replaced with an antigen retrieval step (i.e. incubated in 4 M HCl for 15 min and then neutralised with 0.1 M borate buffer).

Analysis of apoptosis was performed using the DeadEnd™ fluorometric TUNEL system (Promega) and visualised with a Zeiss Axiovision microscope. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) while apoptotic cells were stained with fluorescein isothiocyanate (FITC). Nested analysis of variance (ANOVA) was used to assess statistical significance between treated and untreated samples. A value of *p* \< 0.05 was considered statistically significant.

BrdU labelling of proliferating cells {#Sec5}
-------------------------------------

Twenty-one-day-old mice were injected peritoneally with 0.1 ml of cell proliferation labelling reagent (Amersham) per 10 g of weight and sacrificed after 2 h. The dissected tibias were fixed and analysed by IHC using an anti-BrdU antibody (1:100; Abcam). The number of BrdU-labelled cells was expressed as a proportion of the total population of cells in the proliferative zone. Nested ANOVA was used to assess statistical significance between treated and untreated samples. A value of *p* \< 0.05 was considered statistically significant.

Ultrastructural analysis of cartilage {#Sec6}
-------------------------------------

Ribs from 7-day-old mice were dissected and fixed overnight in 4% PFA/2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer followed by three washes in 0.1 M sodium cacodylate buffer. Samples were then incubated in a secondary fix of 3% potassium ferrocyanide buffer with 2% osmium oxide for 2 h. They were washed in distilled water and incubated overnight for 2 h in 0.5% uranyl acetate at 40°C. The samples were washed in distilled water and dehydrated in increasing concentrations of acetone: 50%, 70%, 90% and 100% acetone for 30 min. The acetone was replaced with two changes of propylene oxide, which in turn was replaced with Spurr's resin. After several changes, the resin was polymerised by incubating at 60°C for 48 h. Seventy-nanometer sections were cut and stained with 0.3% (*w*/*v*) lead citrate, and images were taken on a FEI Tecnai 12 Biotwin electron microscope, recorded on 4489 film (Kodak) and scanned using an Imacon Flextight 848 scanner (Precision Camera & Video).

Phenotypic analysis of the skeleton {#Sec7}
-----------------------------------

Mice at 63 days of age were sacrificed, and bone length measurements were made from whole-body radiographs. At least 20 mice were measured for both treated and control groups, and nested ANOVA was used to assess statistical significance between these two groups. A value of *p* \< 0.05 was considered statistically significant.

Microarray hybridisation {#Sec8}
------------------------

RNA quality was checked using the RNA 6000 Nano Assay and analysed on an Agilent 2100 Bioanalyser (Agilent Technologies). RNA concentration was quantified using a Nanodrop ultra-low-volume spectrophotometer (Nanodrop Technologies). The hybridisation cocktail was hybridised to Mouse 430_2 oligonucleotide arrays (Affymetrix) according to the manufacturers' instructions. Arrays were read using an Agilent GeneArray scanner 3000 7G and processed using Affymetrix GCOS (V1.4) software. Statistical analysis was performed using PUMA an R/Bioconductor package for Propagating Uncertainty in Microarray Analysis (<http://www.bioinf.manchester.ac.uk/resources/puma/index.html>). PPLR is an R package that detects differential gene expression by including probe-level measurement error and calculating the probability of positive log-ratio (PPLR). A PPLR value of 1 indicates significant upregulation whilst PPLR values closer to 0.5 are not significant.

Blood collection and analysis of SPB {#Sec9}
------------------------------------

Whole blood was extracted from mice and pooled into 15-ml fractions, and plasma was isolated by centrifugation. Proteins were precipitated as described elsewhere (Carducci et al. [@CR6]), and the samples were subjected to reverse-phase high-performance liquid chromatography (HPLC) on a reverse-phase C18 synergi 4U hydro 80A column (Phenomenex) as per manufacturer's instructions. Prior to analysis, 4-sodium phenylbutyrate (SPB; special diet services, SCANBUR) and control compounds (phenylacetate and phenylacetylglutamine) were checked for purity by liquid chromatography time of flight mass spectrometry. Control samples were diluted in a range of 10--20 pmol/l for the generation of standard curves.

Cell culture and transfection {#Sec10}
-----------------------------

Chinese hamster ovary-B2 (CHO) cells were cultured in Ham's F-12 media supplemented with 10% FBS, 2 mM [l]{.smallcaps}-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. Human wt matrilin-3 A-domain and the Ile192Asn mutation had previously been sub-cloned into pSecTag2A in-frame to a C-terminal c-myc epitope tag and transfected into CHO cells (Cotterill et al. [@CR7]).

SPB treatment of CHO cell cultures {#Sec11}
----------------------------------

Transfected CHO cells were seeded into 75-cm^2^ vented flasks at a density of ∼1.5 × 10^6^ cells per flask. CHO cells were cultured in SPB (Biomol International, Exeter, UK) administered directly into the culture media at final concentrations of 0 mM (untreated), 0.1, 0.5, 1, 5 and 10 mM. Cells were treated with SPB until confluent at which time protein samples were prepared for SDS-PAGE.

Sample preparation for SDS-PAGE and Western blotting {#Sec12}
----------------------------------------------------

Conditioned media was removed, and the cells were lysed for SDS-PAGE and Western blot analysis. To ensure that equal quantities of protein were analysed, untreated and SPB-treated cells were counted using a haemocytometer and equal numbers of cells were resuspended in 1 ml of culture media as appropriate. Media and lysate protein samples were analysed by SDS-PAGE and Western blotting as described previously (Cotterill et al. [@CR7]).

Results {#Sec13}
=======

In order to obtain sufficient quantities of cartilage for qRT-PCR and Western blotting studies, we decided to use rib and xiphoid cartilage, which are amenable to accurate and reproducible dissection. Therefore, in the first instance, we demonstrated that rib and xiphoid cartilage had a tissue pathology that was comparable to the tibia growth plate.

The cartilage growth plate in ribs and xiphoid is disorganised in mice harbouring the *Matn3* mutation {#Sec14}
------------------------------------------------------------------------------------------------------

H&E staining was performed on tissue sections in order to characterise the differences in growth plate morphology in the mutant mice compared to wild-type controls (Fig. [1a, b](#Fig1){ref-type="fig"}). The growth plates of both the rib and xiphoid cartilage from wt mice were well-organised at 5 and 21 days of age as expected. For example, the demarcation of the individual zones of the growth plate was clearly distinguishable, and chondrocytes in the proliferative zone were arranged in an ordered columnar organisation along the vertical axis of the growth plate (Fig. [1a, b](#Fig1){ref-type="fig"}; black boxes in left panels). However, in the growth plates from mice homozygous for the mutation (m/m), the columnar organisation of the chondrocytes within the proliferative zone was disrupted from 5 days of age, and the chondrocytes, instead of forming ordered columns, were more randomly arranged and generally disorganised (Fig. [1a, b](#Fig1){ref-type="fig"}; red circles in right panels). These observations were consistent with the tibia growth plate as described previously (Leighton et al. [@CR17]). Fig. 1Histological and immunohistochemical analysis of wild-type and mutant xiphoid and rib cartilage. H&E staining of wild-type (wt) and mutant (m/m) **a** rib and **b** xiphoid cartilage growth plates from 5- and 21-day-old mice. Cells in the proliferative zone form ordered columns along the vertical axis of the GP (*black boxes*). In the m/m mice by 5 days of age, the chondrocytes (*red circles*) of the proliferative zone are rounder and more randomly orientated compared to the wt (*black box*). *Scale bar* is 100 µm. IHC with an anti-matrilin-3 antibody on **c** rib and **d** xiphoid growth plates from 5-, 14- and 21-day-old mice. In wild-type mice (wt), matrilin-3 staining was seen in the cartilage ECM at all ages. In mutant mice (m/m), matrilin-3 staining was predominantly within the chondrocytes with only minimal staining present in the ECM. Intracellular staining was observed from 5 days of age and was still present by 21 days of age

Mutant matrilin-3 is retained within the chondrocytes of both rib and xiphoid cartilage {#Sec15}
---------------------------------------------------------------------------------------

IHC staining of wild-type (wt) xiphoid and rib cartilage with an anti-matrilin-3 antibody confirmed that matrilin-3 was found exclusively within the ECM of the growth plate as expected (Fig. [1c, d](#Fig1){ref-type="fig"}). In contrast, IHC analysis of cartilage from mice homozygous for the mutation demonstrated that the majority of matrilin-3 was retained within the chondrocytes and that there was only minimal staining in the ECM. This retention, which was observed in chondrocytes from all regions of the growth plate, is evident by 5 days of age and still present at 21 days of age. These findings were again consistent with the tibia growth plate as described previously (Leighton et al. [@CR17]).

Ultrastructural analysis of cartilage showed enlarged individual cisternae of rER within rib chondrocytes from mutant mice {#Sec16}
--------------------------------------------------------------------------------------------------------------------------

The ultrastructure of rib cartilage from 7-day-old mice was studied by transmission electron microscopy (TEM; Fig. [2](#Fig2){ref-type="fig"} and data not shown). The resting chondrocytes in the growth plates of wild-type mice were evenly distributed and contained organised and folded cisternae of rER that appeared within normal limits (i.e. contained a limited amount of protein material that would be expected in chondrocytes actively synthesising and secreting ECM components). However, in the chondrocytes of cartilage from mutant mice, there were numerous dilated cisternae of rER that contained large amounts of amorphous material and which was confirmatory of retained protein (Fig. [2](#Fig2){ref-type="fig"}). Dilated rER was seen in all of the chondrocytes of the mutant cartilage, and very few normal cisternae were present. Fig. 2Ultrastructural analysis of 7-day-old rib cartilage using TEM shows enlarged rER cisternae in mutant chondrocytes. Mutant chondrocytes in the resting (*asterisk*) and proliferative (*arrow*) zones of the growth plate have dilated cisternae of rER compared to wild-type chondrocytes from the same regions. Mutant hypertrophic chondrocytes contain the remnants of intracellular protein (*arrowhead*) which is not seen in wild-type hypertrophic chondrocytes

In the wild-type growth plate, the proliferative cells were flatter than resting chondrocytes and formed well-organised and tightly stacked two-, four- and eight-cell chondrons. However, in cartilage from mutant mice, the proliferative cells were generally slightly enlarged due to their dilated cisternae, which affected the spatial organisation of individual cells within the chondrons since they were unable to align as closely (data not shown).

The hypertrophic chondrocytes in the wild-type growth plates were generally rectangular in shape, and the condensed chromatin was clearly visible. However, in mutant mice, the hypertrophic cells were more irregular in shape, and there were clear remnants of intracellular protein (Fig. [2](#Fig2){ref-type="fig"}).

Overall, these pathological findings were consistent with those seen in the tibia growth plate as described previously (Leighton et al. [@CR17]) and validated the use of rib and xiphoid cartilage for gene and protein expression studies. However, in characterising these tissues, we noted that after approximately 7 days of age the central part of the ribs began to ossify, which significantly reduced the number of chondrocytes that could be isolated. We therefore decided to use rib cartilage for the 5-day study and xiphoid cartilage for the 21-day study.

Gene expression profiling shows a significant activation of the UPR in mutant chondrocytes at 5 days of age that is still maintained at 21 days of age {#Sec17}
------------------------------------------------------------------------------------------------------------------------------------------------------

In order to determine the differential gene expression caused by the *Matn3* V194D mutation, we chose to perform an Affymetrix genechip microarray hybridisation using RNA isolated from 5-day-old rib chondrocytes. We chose to concentrate on the 20 most significantly upregulated genes that were directly related to ER stress, UPR and/or protein folding, and these are summarised in Table [1](#Tab1){ref-type="table"}. Table 1A microarray hybridisation was performed on RNA isolated from the chondrocytes of 5-day-old rib cartilage from wild-type and mutant miceGene and/or protein nameGene symbolNCBI mouse gene IDFold change (mut vs. wt)Cysteine-rich with EGF-like domains 2*Creld2*767375.77Heat shock protein 90 kDa beta (Grp94), member 1*Grp94*/*Hsp90b1*220274.59Transformation-related protein 53 binding protein 1*Trp53bp1*272234.58Arginine-rich, mutated in early stage tumours*Armet*3159894.29Protein disulfide isomerase-associated 6*Pdia6*718533.18Protein disulfide isomerase-associated 4 (Erp72)*Erp72*/*Pdia4*123043.16DnaJ (Hsp40) homologue, subfamily A, member 4*Dnaja4*582333.06Solute carrier family 35, member B1*Slc35b1*1101722.61Serine (or cysteine) peptidase inhibitor, clade A, member 3 N*Serpina3n*207162.29Mannoside acetylglucosaminyltransferase 2*Mgat2*2176642.11DnaJ (Hsp40) homolog, subfamily C, member 3*Dnajc3*1000372582.57Signal peptidase complex subunit 3 homolog (S. cerevisiae)*Spcs3*3174092.50Heat shock 70 kDa protein 5 (glucose-regulated protein BiP)*BiP/Hspa5*148282.46Signal peptidase complex subunit 2 homolog (S. cerevisiae)*Spcs2*666242.16DnaJ (Hsp40) homologue, subfamily B, member 1*Dnajb1*814892.10Calnexin*Canx*123302.10Protein disulfide isomerase-associated 3 (Erp 57)*Erp57/Pdia3*148272.03Calreticulin*Calr*123171.95Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1*Herpud1*642091.83Nucleobindin 1*Nucb1*182201.82The relative expression levels of the 20 most upregulated genes with a relevant significance (PPLR) value of 1 are shown. PPLR is an R package that detects differential gene expression by including probe-level measurement error and calculating the probability of positive log-ratio (PPLR). A PPLR value of 1 indicates significant upregulation whilst PPLR values closer to 0.5 are not significant. The gene/protein name is the one recorded by the Affymetrix microarray software, and the NCBI geneID has been included as a reference. Note that PDI itself is not represented on the microarray chip but that the other family members Pdia2-6 are present

In order to validate some of these microarray data, we performed qRT-PCR and Western blot analysis on a selection of genes (Fig. [3](#Fig3){ref-type="fig"}). Real-time PCR analysis confirmed a significant ∼2.4-fold increase in BiP and a ∼4.5-fold increase in Grp94. In addition, ERp72, calnexin (canx) and calreticulin (calr) were also significantly upregulated by ∼2.7-, ∼2.8- and ∼2.8-fold, respectively (Fig. [3a](#Fig3){ref-type="fig"}). To verify the protein levels of individual chaperones, Western blots were performed for Grp94, BiP, ERp72 and PDI, and these were found to have significant fold increases of ∼1.5, ∼1.4, ∼2.6 and ∼1.3, respectively (Fig. [3b, c](#Fig3){ref-type="fig"}). A summary of the gene and protein expression levels for the upregulated chaperones is presented in Fig. [3d](#Fig3){ref-type="fig"}. Overall, these data confirm a significant activation of the UPR in the chondrocytes of 5-day-old mice homozygous for the *Matn3* V194D mutation. Fig. 3qRT-PCR and Western blot validation of ER stress and UPR markers in chondrocytes from 5-day-old mutant mice. **a** qRT-PCR was used to validate the relative levels of gene expression in mutant (m/m) chondrocytes compared to wild-type (wt) chondrocytes. In all cases, the levels of mRNA was normalised against 18S RNA. The relative levels of BiP, Grp94, ERp72, calnexin (Canx) and calreticulin (Calr) mRNA were increased between ∼2-fold and ∼4-fold in mutant chondrocytes \[*n* = 3 litters per genotype (approximately five to ten mice per litter) and three separate experiments were performed in duplicate; independent *t* test \**p* \< 0.05 or \*\**p* \< 0.01)\]. **b** Total cellular protein was isolated from aliquots of 2 × 10^5^ wt and m/m chondrocytes and analysed by SDS-PAGE and Western blotting using antibodies against Grp94 (∼94 kDa), BiP (∼76 kDa), ERp72 (∼72 kDa) and PDI (∼58 kDa). Western blotting consistently showed that the levels of these four proteins were increased in m/m samples compared to wt. \[*n* = 3 litters per genotype (∼5--10 mice per litter) and three separate experiments were performed in duplicate; independent *t* test \**p* \< 0.05 or \*\**p* \< 0.01)\]. **c** The Western blots were scanned and analysed by densitometry, which showed that there was a 1.5-fold increase in Grp94, 1.4-fold increase in BiP, 2.6-fold increase in ERp72 and a ∼1.3-fold increase in PDI. **d** Comparison of the relative expression levels determined by microarray, qRT-PCR and Western blotting all showed an upregulation of key molecular chaperones

We also investigated the UPR in chondrocytes from the xiphoid cartilage of wild-type and mutant mice at 21 days of age. Western blots showed that there was still an increased level of ER stress in mutant chondrocytes compared to wild type. For example, BiP was upregulated by ∼1.3-fold, ERp72 by ∼1.7-fold and Grp94 by ∼3-fold (Fig. [4a](#Fig4){ref-type="fig"}). Furthermore, IHC staining performed using an anti-Grp94 antibody showed stronger staining in the xiphoid growth plate from 21-day-old mutant mice (Fig. [4b](#Fig4){ref-type="fig"}). Fig. 4The UPR is maintained at 21 days of age in mutant chondrocytes from xiphoid cartilage. **a** Western blot densitometry shows an upregulation of chaperones in chondrocytes from the xiphoid cartilage of 21-day-old mutant mice. Erp72 was upregulated by ∼1.8-fold, Grp94 by ∼3-fold and BiP by ∼1.3-fold, respectively. \[*n* = 3 mice per genotype and three separate experiments were performed in triplicate, independent *t* test \**p* \< 0.05\]. **b** IHC staining performed using an anti-Grp94 antibody showed stronger staining in the xiphoid growth plate from 21-day-old mutant mice, particularly in chondrocytes from the proliferative zone

In order to characterise further the UPR in mutant chondrocytes at 5 days of age, we also examined the downstream mediators of the ER stress response, which included the cleavage of the ER membrane-anchored transcription factor ATF6 and the activation by splicing of transcription factor X-bp1. Both of these factors have been shown to be activated in a mouse model of PSACH-MED caused by a *Comp* mutation (Pirog-Garcia et al. [@CR23]) and the former in a mouse model of MCDS caused by a mutation in *col10a1* (Rajpar et al. [@CR24]). We saw no evidence of the cleavage of ATF6 in either the wild-type or mutant chondrocyte protein extractions, compared to a positive control from the MCDS mouse (Supplemental Fig. S[1](#MO8){ref-type=""}). Furthermore, there were no differences between the splicing of X-bp1 mRNA in either wild-type or mutant chondrocytes.

ER stress does not lead to increased chondrocyte apoptosis in rib cartilage at 5 days of age {#Sec18}
--------------------------------------------------------------------------------------------

We have previously reported that there is dysregulated chondrocyte apoptosis at 3 weeks of age in the tibia growth plates of mice homozygous for the mutation (Leighton et al. [@CR17]). We therefore wished to determine the pathological effect of ER stress and the UPR on chondrocyte viability at 5 days of age. TUNEL assays were performed to quantify the relative levels of chondrocyte apoptosis in the growth plates of ribs from wild-type and mutant mice; however, there were no significant differences in the relative numbers, or position, of TUNEL-positive cells between the different genotypes. Approximately 1.96% of cells were TUNEL positive in the hypertrophic zone of growth plates from wild type mice, whilst 1.98% of cells were TUNEL positive in the hypertrophic zone of mutant mice, but this small increase in apoptosis was not statistically significant (Fig. [5a](#Fig5){ref-type="fig"}). Furthermore, the expression of CHOP, an ER-stress-mediated pro-apoptotic factor, was slightly but significantly downregulated in mutant cells at 5 (rib) and 21 (xiphoid) days of age as determined by qRT-PCR (Fig. [5b](#Fig5){ref-type="fig"}). Finally, there was no change in the anti-apoptotic factor *Bcl2* in mutant chondrocytes from ribs at 5 days of age as measured by densitometry of Western blots (Fig. [5c](#Fig5){ref-type="fig"}). Fig. 5TUNEL assay, CHOP and Bcl-2 analysis in chondrocytes of cartilage from wild-type and mutant mice at 5 (rib) and 21 (xiphoid) days of age. **a** End-stage apoptosis (DNA fragmentation) was measured in the ribs of 5-day-old mice using TUNEL assay. The relative levels of apoptosis were calculated by comparing the number of apoptotic chondrocytes (FITC-labelled nuclei) with the total number of chondrocytes in the hypertrophic zone (DAPI-labelled nuclei + FITC-labelled nuclei). TUNEL assay showed that there were no differences in the relative levels of apoptosis between mutant and wild-type chondrocytes from 5-day-old mice \[*n* \> 20 sections per genotype, independent *t* test\]. **b** Chondrocytes were isolated from the ribs of 5-day-old mice and the xiphoid of 21-day-old mice, and the RNA was extracted. The relative levels of CHOP mRNA in mutant chondrocytes compared to wt chondrocytes are shown at 5 and 21 days of age. The mRNA levels were normalised against 18S RNA. There was a modest, but significant, reduction in CHOP mRNA in mutant chondrocytes. \[*n* = 3 litters per genotype (five to ten mice per litter) and three separate experiments were performed in duplicate, independent *t* test \**p* \< 0.05\]. **c** Total cellular protein from 5-day-old rib cartilage was analysed by SDS-PAGE and Western blotting with anti-Bcl2. Representative Western blots show similar levels of Bcl-2 protein in mutant cells compared to wild type. Densitometry confirmed that there was no statistically significant difference in Bcl-2 levels between wild type and mutant. \[*n* = 3 mice per genotype (five to ten mice per litter) and three separate experiments performed in triplicate, independent *t* test\]

The effect of treating mutant mice with sodium phenylbutyrate as an aid to alleviate the phenotype {#Sec19}
--------------------------------------------------------------------------------------------------

Mutant mice were fed standard mouse chow pellets supplemented with SPB at a concentration of 7 g/kg diet (effective daily consumption ∼1 g SPB/kg body weight) in an attempt to aid the folding and secretion of mutant matrilin-3 and alleviate the ER stress/UPR. Untreated mice were fed with food without SPB. Quantification of blood plasma showed the presence of SPB at a concentration of 100 μmol/l. Furthermore, SPB was detected in the stomachs of mice whose diet consisted of milk from their mothers who themselves were on the SPB diet (data not shown).

Microarray hybridisation was performed using RNA isolated from rib chondrocytes of 5-day-old mutant mice to characterise the changes in gene expression following treatment with SPB (i.e. treated mutant mice vs. untreated mutant mice). The expression levels of the major chaperones BiP, Grp94, calnexin, ERp72, calreticulin and ERp57 were unchanged in treated mice compared to untreated mice (Table [2](#Tab2){ref-type="table"}). However, at 21 days of age, the protein levels of the chaperones BiP, Grp94 and Erp72 were slightly, but significantly, downregulated by ∼0.74-fold, ∼0.69-fold and ∼0.79-fold, respectively, in the xiphoid chondrocytes of the treated mice (Fig. [6](#Fig6){ref-type="fig"}). Table 2Microarray hybridisations were performed on RNA isolated from rib chondrocytes of 5-day-old treated and untreated mutant miceChaperoneExpression fold change (treated vs untreated)Significance value (PPLR)Expression levels (microarray)ControlTreatedBiP1.010.526,346.8566,437.842Grp941.080.3239.19423836.16048094Erp72 (Pdia4)1.040.434716.4064688.284Calreticulin1.000.5123,529.29093,550.645517Erp 57 (Pdia3)1.060.3295,520.8955,173.721Calnexin1.050.6593,312.77123,489.222069There were no changes in the expression levels of key chaperone genes. *N* = 3 litters (of eight to ten mice per litter) per sample (treated and untreated) mutant mice and three separate experiments were performed in duplicate. A significance (PPLR) value of 1 indicates significant upregulation whilst PPLR values closer to 0.5 are not significantFig. 6Chaperone protein levels are reduced in treated mice at 3 weeks of age. Densitometry of Western blots of chondrocyte total protein from xiphoid cartilage of 21-day-old treated and untreated mutant mice. The chaperone protein levels at 21 days of age are slightly, but significantly, downregulated in the chondrocytes from the treated mutant mice. There was a ∼0.79-fold decrease in Erp72, ∼0.74-fold decrease in Grp78 and a ∼0.69-fold decrease in Grp94. \[*n* = 3 mice per group (treated and untreated) and two pooled cartilage samples were used in three separate experiments performed in triplicate; independent *t* test \**p* \< 0.05\]

Nevertheless, SPB treatment did not improve the phenotype of the mutant mice as determined by body weights and bone length measurements of 21-day-old mice, which were indistinguishable between untreated and treated mice (Fig. [7a, b](#Fig7){ref-type="fig"}). Interestingly, TUNEL assays performed on 3-week-old tibia growth plates showed that 0.51% of cells in the hypertrophic zone were TUNEL positive in the sections from SPB-treated mutant mice compared to 0.62% in the sections from untreated mice, which equates to a 17% decrease in apoptosis (Fig. [7c](#Fig7){ref-type="fig"}). The relative levels of TUNEL-positive chondrocytes at the vascular invasion front (VIF) were 1.4% in the sections from SPB-treated mice compared to 1.1% in untreated mice (Fig. [7d](#Fig7){ref-type="fig"}). Furthermore, there was an increase in chondrocyte proliferation in the proliferative zone of growth plates from SPB-treated mice as determined by BrdU labelling. Within the proliferation zone of SPB-treated mice, 12.3% of cell nuclei were labelled with BrdU, whilst in the same region of the untreated samples only 11.4% of cell nuclei were labelled, thus representing an 8% increase in chondrocyte proliferation (Fig. [7e](#Fig7){ref-type="fig"}). However, the differences in both apoptosis and cell proliferation were not found to be statistically significant using nested ANOVA analysis. We performed similar studies with a mouse model of Schmid metaphyseal chondrodysplasia (Rajpar et al. [@CR24]), but again this treatment did not improve the phenotype (Supplemental Fig. S[2](#MO9){ref-type=""}). Fig. 7The effect of SPB treatment on the phenotype of mutant mice and the relative levels of matrilin-3 retention, chondrocyte proliferation and apoptosis. **a** Bone length measurements of treated and untreated mutant male mice were performed on radiographs taken at 9 weeks of age showed no significant differences. Measurements were made of the inner canthal distance (*ICD*), femur (*F*), pelvis (*P*) and tibia (T). (*n* \> 23 mice per group; nested ANOVA). **b** The body weights of male and female mutant mice showed no significant differences between untreated and treated groups. (*n* \> 23 mice; nested ANOVA). The relative levels of apoptosis in **c** the hypertrophic zone (HZ) and **d** at the VIF of the growth plate was calculated by counting the number of TUNEL-positive chondrocytes in the HZ or at the VIF compared to the total number of DAPI-stained chondrocytes in the growth plate. Although there appeared to be relatively less TUNEL-positive cells in the HZ and more apoptosis at the VIF in the treated group, these differences were not statistically significant. (*n* \> 20 sections per group; nested ANOVA). **e** Twenty-one-day-old mice were administered with 0.01 ml/g of the nucleotide analogue BrdU 2 h prior to sacrifice. IHC was performed on tibia sections using an anti-BrdU antibody. The relative levels of chondrocyte proliferation was determined by counting the number of BrdU-labelled nuclei compared to the total number of chondrocytes in the proliferative zone of the growth plate. There were no significant differences in the proportion of proliferating cells between the treated and untreated groups. (*n* \> 20 sections per group; nested ANOVA). **f** IHC using anti-matrilin-3 antibody on tibia growth plates from 21-day-old mutant mice either treated or untreated with SPB. In both groups, there is extensive intracellular retention of mutant matrilin-3 (*scale bar* is 100 µm)

Finally, to determine whether treatment with SPB aids the secretion of mutant protein into the ECM, we used IHC staining on fixed sections from 3-week-old tibia growth plates. However, there was no apparent improvement in the secretion of mutant matrilin-3 in SPB-treated mice since matrilin-3 staining was indistinguishable in tibia growth plates from treated and untreated mutant mice (Fig. [7e](#Fig7){ref-type="fig"}).

We wished to determine if SPB could aid in the secretion of mutant protein from a cell culture model of mutant matrilin-3 A-domains that we have previously characterised (Cotterill et al. [@CR7]; Fresquet et al. [@CR9]). Increasing concentrations of SPB (0.1 to 10 mM) failed to aid the secretion of the mutant matrilin-3 A-domain (Supplemental Fig. S[3](#MO10){ref-type=""}); however, we did notice that the addition of SPB up to a final concentration of 5 mM increased the expression of both wild-type and mutant proteins. The addition of 10 mM SPB reduced the yields of recombinant protein, although they were still higher than without the addition of SPB (Supplemental Fig. S[3](#MO10){ref-type=""}) and also had a detrimental effect on cell viability regardless of whether the cells were expressing mutant or wild type matrilin-3 A-domains (not shown).

Discussion {#Sec20}
==========

The aim of this study was to characterise the initial cellular response to the expression of mutant matrilin-3 with the intention of identifying the key genetic pathway(s) that are ultimately responsible for decreased chondrocyte proliferation and dysregulated apoptosis at 3 weeks of age (Leighton et al. [@CR17]). Our data from this current study demonstrate that a UPR is rapidly activated in the post-natal period, which is most likely due to accumulation of misfolded matrilin-3 within the rER of growth plate chondrocytes.

We initially demonstrated that rib and xiphoid cartilage from mutant animals displayed a tissue pathology that was similar to that previously reported for the growth plates of the major long bones (i.e. femur and tibia; Leighton et al. [@CR17]). This disease pathology is characterised by the intracellular retention of mutant matrilin-3 from birth and a generalised growth plate dysplasia characterised by abnormal chondrocyte morphology and their misalignment within the proliferative zone. This observation suggests that weight bearing is not a factor in the expression and intracellular retention of mutant matrilin-3, which is consistent with similar findings in a pseudoachondroplastic Scottish deerhound (Stevens [@CR29]). Our findings therefore confirm that MED is a generalised cartilage disorder (chondrodysplasia), which manifests itself most profoundly in the growth of the long bones.

The UPR that is activated in mutant chondrocytes in vivo is characterised by the upregulation of key chaperones that are known to be associated with ER stress responses or protein folding and quality control. These include BiP (which is a member of the Hsp70 family), Grp94, members of the Hsp40 protein family (*Dnajb1*, *Dnajc3 and Dnaja4*) and also *Pdia3* (ERp57), *Pdia4* (ERp72) and *Pdia6*. The PDI family of protein disulphide isomerase-associated proteins (PDIA2-6) are ER resident proteins that catalyse in turn the formation, reduction and isomerisation of disulphide-bonded proteins such as matrilin-3 (Hatahet and Ruddock [@CR11]). PDI can also interact with the lectin chaperones calreticulin and calnexin, which were also increased in mutant chondrocytes. Calnexin and calreticulin bind to and mediate the folding of newly synthesised glycoproteins and are important in monitoring the N-linked glycans that persist on unfolded or misfolded glycoproteins. The increased expression of these two genes in mutant chondrocytes might be expected since matrilin-3 has a potential N-linked glycosylation site (Wagener et al. [@CR33]). The upregulation of *Mgat2* is further evidence that mutant matrilin-3 is being recognised and processed by the Canx/Calr folding pathway. *Mgat2* encodes a Golgi enzyme called monoacylglycerol acyltransferase 2, which catalyses an essential step in the conversion of oligomannose to complex N-glycans, and mice deficient in *Mgat2* have a congenital disorder of glycosylation type IIa (Wang et al. [@CR35]). Furthermore, patients with the autosomal recessive disease carbohydrate-deficient glycoprotein syndrome type II have been shown to have mutations in *MGAT2* (Tan et al. [@CR31]).

We have previously shown in a cell culture model (Cotterill et al. [@CR7]) that mutant matrilin-3 A-domains are predominantly unfolded in the rER of cells and are directly associated with ERp72 (*Pdia4*), a member of the protein disulphide isomerase family. This is consistent with the ∼3-fold increase in the expression of *Pdia4* in mutant mouse chondrocytes (Table [1](#Tab1){ref-type="table"}). Interestingly, in the cell culture system, no direct association was seen with PDI, BiP or Grp94, and this disparity in the chaperone protein profile between the in vitro and in vivo studies is most likely due to differences in the recognition and processing of full-length mutant matrilin-3 (this study) compared to the mutant A-domain alone (Cotterill et al. [@CR7]). For example, the potential N-linked glycosylation site of matrilin-3 is in the second EGF-like domain between residues (Asn^321^--Gly^322^--Ser^323^) and not the A-domain (Wagener et al. [@CR33]).

In addition to chaperone/heat shock proteins and members of the lectin/PDI folding complexes, we also identified genes by the microarray studies that are known to play a role in ER-associated degradation such as homocysteine-inducible, endoplasmic-reticulum-stress-inducible, ubiquitin-like domain member 1 (*Herpud1*; Kim et al. [@CR16]), suggesting that some misfolded matrilin-3 might be targeted for degradation.

Finally, amongst the genes whose expression was upregulated in mutant chondrocytes were several genes that have only recently been implicated in ER stress. For example, cysteine-rich with EGF-like domains 2 (*Creld2*), which was the most highly upregulated gene in mutant chondrocytes has recently been reported as a novel ER-stress-inducible gene (Oh-hashi et al. [@CR19]). The promoter region of *Creld2* contains a typical ER-stress-responsible element (ERSE) and, whilst it is believed to be involved in the folding and transport of proteins through the ER and Golgi, its precise role has yet to be determined (Ortiz et al. [@CR20]). Another gene over-expressed to a similar extent as *Creld2* was arginine-rich, mutated in early stage of tumours (*Armet*; also known as MANF), which is known to be activated by the UPR via an ERSE-II element (Mizobuchi et al. [@CR18]). Furthermore, over-expression of *Armet* in cell culture has been shown to inhibit cell proliferation and ER-stress-induced apoptosis (Apostolou et al. [@CR1]), both of which are key features of the growth plate dysplasia in the MED-*Matn3* mouse model (Leighton et al. [@CR17]).

We were able to determine that the post-natal activation of a UPR in mutant chondrocytes did not result in an immediate increase and/or dysregulation of CHOP-mediated apoptosis by 5 days of age. Furthermore, our data suggest that at 5 days of age the UPR is still primarily BiP-mediated and has not progressed to other downstream mediators, such as the IRE1 and PERK receptors as shown by a lack of ATF6 cleavage or X-bp1 splicing. Unfortunately, due to technical constraints, it was not possible to examine chondrocyte proliferation at this age since the mice are too small for peritoneal injection. In the long term, however, determining the precise time of onset of reduced chondrocyte proliferation and spatially dysregulated apoptosis in vivo will be important for understanding the disease process and delineating the influence of these two pathological components of MED.

We hypothesised that alleviating the rER stress and/or UPR in mutant chondrocytes may have an impact on cell phenotype and might lessen or even prevent the reduction in cell proliferation and increase spatially dysregulated apoptosis, eventually restoring normal long-bone growth. SPB is a butyrate analogue that is approved for clinical use as an ammonia scavenger in subjects with urea cycle disorders. It is also a known transcriptional regulator that may act by inhibiting histone deacetylase (Candido et al. [@CR5]). Previous studies have shown that SPB has properties that aid the trafficking and secretion of mutant proteins in a variety of protein folding diseases such as cystic fibrosis (Rubenstein and Zeitlin [@CR25]), hereditary hemochromatosis (de Almeida et al. [@CR8]) and glaucoma (Tsang et al. [@CR32]) and has been found to prevent aggregation of proteins in vitro in neurodegenerative diseases (Ryu et al. [@CR27]). Finally, oral dosage of SPB improved the phenotype in a mouse model of type 2 diabetes (Ozcan et al. [@CR22]) that was linked to ER cell stress (Ozcan et al. [@CR21]).

We used a similar dosage protocol to that of Ozcan et al. ([@CR22]); however, SPB administered at this dosage in the food did not have an effect on MED disease severity as determined by body weight and bone length measurements at 9 weeks of age. Furthermore, there was no significant improvement in chondrocyte proliferation and apoptosis at 3 weeks of age. Although there appeared to be a modest increase (∼8%) in chondrocyte proliferation at 3 weeks of age, this was not statistically significant, which might in part be due to the natural variability between litters. Furthermore, at 5 days of age, microarray analysis showed no changes in the expression levels of chaperones in mutant chondrocytes following treatment with SPB. Nevertheless, by 3 weeks of age, there was a modest but significant decrease in the protein levels of ERp72, BiP and Grp94, but ultimately this did not affect the trafficking of mutant matrilin-3, which remained predominately intracellular regardless of whether the mice were treated with SPB or not. SPB is known to regulate general transcription due to its role as a histone deacetylase inhibitor. The microarray results for \[m/m vs. wt\] and \[treated vs. untreated\] had a similar overall proportion of downregulated genes with 47% of genes downregulated in \[m/m vs. wt\] and 43% of genes downregulated in \[treated vs. untreated\], suggesting that SPB did not have a major effect on the global transcription of genes in chondrocytes.

In a parallel study, we also investigated the effect of SPB treatment on a mouse model of metaphyseal chondrodysplasia type Schmid (MCDS) that we have recently described (Rajpar et al. [@CR24]). However, like the *Matn3*-MED mouse, SPB treatment failed to improve the disease phenotype.

One possible reason for the SPB treatment having no effect on mutant matrilin-3 secretion, ER stress, chondrocyte proliferation and apoptosis may be due to the avascular nature of cartilage. There are no blood capillaries within cartilage, and only the perichondrium is vascularised. Instead, chondrocytes get their nutrient supply by diffusion from blood vessels of the perichondrium. Compressive loading of cartilage creates a pumping action due to the gel-like and hydrated nature of cartilage that facilitates this diffusion. Since there is no readily accessible blood supply to the chondrocytes, this will limit the diffusion of SPB into the chondrocytes. Therefore, it is possible that SPB takes time to enter the chondrocytes or may not be reaching them at all. Targeting of SPB directly into cartilage may help to overcome this potential problem. However, we were unable to show that treatment with SPB could aid in the secretion of mutant matrilin-3 A-domains in vitro. Interestingly, treatment with SPB up to 5 mM did increase the overall expression of recombinant protein and may be acting by reducing the ER stress in cells induced to over-express a recombinant protein. This finding is outside the scope of the current study but deserves further investigation.

In summary, MED is caused by a defect in the trafficking and secretion of mutant matrilin-3 that causes ER stress and a UPR in the post-natal period. Treatment with SPB may have an effect on ER stress and UPR at later stages of the disease, but it is too late or has insufficient efficacy to influence the disease phenotype. However, these preliminary studies using chemical chaperones will hopefully pave the way for developing suitable therapies for patients with MED and related diseases.
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**a** RT-PCR analysis of X-bp1 splicing in mRNA from wild-type (wt) and mutant (mut) chondrocytes at 5 days of age. mRNA from two different mutant mice were analysed. Key: *m* molecular weight marker, *u* unsliced X-bp1 control, *s* spliced X-bp1 control to show expected size of fragments at 250 and 220 bp, respectively. **b** SDS-PAGE Western blotting of total cellular proteins obtained from wild-type (wt) and mutant (mut) chondrocytes at 5 days of age. Full-length ATF6 (∼90 kDa) was present in wt and mut proteins samples, and we did not observe any cleaved ATF6 in protein samples from the *Matn3* mouse. The positive control (**c**) is chondrocyte proteins from the MCDS mouse model (see Rajpar et al. [@CR24]), which readily shows the cleaved form (∼50 kDa and indicated by *arrow*). A non-specific band at ∼70 kDa (*asterisk*) was also observed and has been reported previously (GIF 61 kb)
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High resolution image (TIFF 490 kb)
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SPB has no overt effect upon bone growth or histological appearance of the growth plate in the *Col10a1* p.N617K MCDS mouse (Rajpar et al. [@CR24]). **a** In utero treatment: timed matings between males and females homozygous for the *Col10a1* mutation (m/m) were established and pregnant females administered SPB via gavage from 13.5 days post coitum until they gave birth (1 g SPB/kg body weight/day divided given as two doses approximately 12 h apart). Mice were humanely sacrificed at birth, and the knee joints dissected and fixed for IHC analysis. Treatment with SPB had no effect on growth plate morphology (H&E) or on retention of mutant type X collagen within the hypertrophic chondrocytes shown using immunohistochemistry (ColX IHC; *scale bar* = 100 µm). The *red lines* indicated the extent of the hypertrophic zone. **b** SPB was incorporated into standard mouse chow pellets (7 g SPB per kg chow) in order to achieve a daily dose of approximately 1 g per kg body weight. Mice were sacrificed at specified ages and radiographed to determine bone lengths. (*i*) Knee joints were processed for histology and hypertrophic zone widths (*ii*) determined from images of H&E-stained sections. There were no significant differences between treated and untreated groups for either bone lengths or hypertrophic zone widths as assessed by ANOVA (GIF 426 kb)
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High resolution image (TIFF 2229 kb)
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SDS-PAGE and Western blot analysis of conditioned media (**a**) and cell lysates (**b**) from CHO cells stably transfected with WT and I192N mutation containing recombinant MATN3 A-domain under non-reducing conditions. CHO cells grown in untreated (U), 0.1, 0.5, 1, 5 and 10 mM SPB were analysed to detect the levels of correctly folded and disulphide-bonded recombinant A-domain in response to SPB treatment using anti-c-myc antibodies. I192N mutant cell lysate samples were ran along with a wild-type untreated control to indicate where the correctly folded and disulphide-bonded A-domain runs to during SDS-PAGE. Molecular weights of proteins are indicated in kilodalton (GIF 174 kb)
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High resolution image (TIFF 652 kb)

This work was supported by grants from the Wellcome Trust (MDB is the recipient of a Wellcome Trust Senior Research Fellowship in Basic Biomedical Science; Grants 071161/Z/03/Z and 084353/Z/07/Z), the Arthritis Research Campaign (SN was the recipient of an ARC Ph.D. studentship) and European Commission FP6 (LSHM-CT-2007-037471). The research was undertaken in the Wellcome Trust Centre for Cell-Matrix Research and the Histology, Microarray and Transgenic Core Facilities of the Faculty of Life Sciences at the University of Manchester. Electron microscopy was performed by Roger Meadows.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
